Home » Stocks » GERN

Geron Corporation (GERN)

Stock Price: $1.34 USD -0.03 (-2.19%)
Updated May 6, 2021 4:00 PM EDT - Market closed
Market Cap 427.47M
Revenue (ttm) 253,000
Net Income (ttm) -75.62M
Shares Out 271.46M
EPS (ttm) -0.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 6
Last Price $1.34
Previous Close $1.37
Change ($) -0.03
Change (%) -2.19%
Day's Open 1.38
Day's Range 1.31 - 1.38
Day's Volume 2,457,838
52-Week Range 1.23 - 2.40

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today announced that it will release its first quarter 2021 financial results after the market closes on Monday, May 10, 2021 via p...

3 days ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 220,000 shares of Geron common stock as ...

2 weeks ago - Business Wire

SAN FRANCISCO, April 19, 2021 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of Geron Corporation (NASDAQ: GERN) relating to possib...

2 weeks ago - PRNewsWire

Geron (GERN) is evaluating its lead pipeline candidate, imetelstat, in late-stage studies for refractory myelofibrosis and myelodysplastic syndromes.

3 weeks ago - Zacks Investment Research

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today announced that the first patient has been dosed in IMpactMF, the Phase 3 clinical trial evaluating imetelstat, a first-in-cla...

3 weeks ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 240,000 shares of Geron common stock as ...

1 month ago - Business Wire

The company released its latest quarterly update, and investors were not impressed.

1 month ago - The Motley Fool

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic...

1 month ago - Business Wire

Geron (NASDAQ:GERN) announces its next round of earnings this Thursday, March 11. Here is Benzinga's everything-that-matters guide for this Thursday's Q4 earnings announcement.

1 month ago - Benzinga

Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today announced that it will release its fourth quarter and full year 2020 financial results after the market closes on Thursday, Ma...

2 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 431,600 shares of Geron common stock as ...

2 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 120,000 shares of Geron common stock as ...

3 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer...

3 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the opening for patient screening and enrollment of the IMpactMF ...

4 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced achievement of fifty percent enrollment in the IMerge Phase 3 cli...

4 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that four oral presentations and six poster presentations contain...

4 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 80,000 shares of Geron common stock as ...

5 months ago - Business Wire

Geron Corporation (GERN) John Scarlett Presents at 2020 Stifel Virtual Healthcare Conference (Transcript)

5 months ago - Seeking Alpha

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer...

5 months ago - Business Wire

Geron Corp (GERN) CEO John Scarlett on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Geron (GERN) delivered earnings and revenue surprises of -20.00% and 44.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Shares of Geron (NASDAQ:GERN) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share increased 25.00% over the past year to ($0.06), which were in line with the ...

6 months ago - Benzinga

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that ten abstracts containing clinical data and analyses related ...

6 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today announced that it will release its third quarter 2020 financial results after the market closes on Thursday, November 5, 2020...

6 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that data from the IMerge Phase 2 trial were published in the Jou...

6 months ago - Business Wire

Geron (GERN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it has entered into a loan facility for up to $75 million wi...

Other stocks mentioned: HTGC
7 months ago - Business Wire

Geron (GERN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 80,000 shares of Geron common stock as ...

7 months ago - Business Wire

Geron Corporation (GERN) CEO John Scarlett Presents at H.C. Wainwright Global Investment Conference Transcript

7 months ago - Seeking Alpha

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A.

7 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 270,000 shares of Geron common stock as ...

8 months ago - Business Wire

Geron Corp (GERN) CEO John Scarlett on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2020.

9 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A.

9 months ago - Business Wire

MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today announced that it will release its second quarter 2020 financial results after the market closes on Thursday, August 6, 2020 v...

9 months ago - Business Wire

Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

Geron has been struggling lately, but the selling pressure may be coming to an end soon

9 months ago - Zacks Investment Research

Is (GERN) Outperforming Other Medical Stocks This Year?

9 months ago - Zacks Investment Research

MENLO PARK, Calif., July 01, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the European Medicines Agency (EMA) Commit...

10 months ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor in Geron.

10 months ago - Zacks Investment Research

Investors need to pay close attention to Geron Corporation (GERN) stock based on the movements in the options market lately.

10 months ago - Zacks Investment Research

MENLO PARK, Calif., June 12, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that an oral presentation and three poster pres...

10 months ago - GlobeNewsWire

Geron Corporation (GERN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

10 months ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for June 9th

Other stocks mentioned: EBAY, KOPN, RH
10 months ago - Zacks Investment Research

Geron Corporation (GERN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

10 months ago - Zacks Investment Research

Is (GERN) Outperforming Other Medical Stocks This Year?

11 months ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for June 5th

Other stocks mentioned: AXU, CODX, RH
11 months ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for June 2nd

Other stocks mentioned: AT, AXU, GSV
11 months ago - Zacks Investment Research

About GERN

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquarte... [Read more...]

Industry
Biotechnology
IPO Date
Jun 30, 1996
CEO
John Scarlett
Employees
53
Stock Exchange
NASDAQ
Ticker Symbol
GERN
Full Company Profile

Financial Performance

In 2020, Geron's revenue was $253,000, a decrease of -45.00% compared to the previous year's $460,000. Losses were -$75.62 million, 10.3% more than in 2019.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for Geron stock is "Strong Buy." The 12-month stock price forecast is 4.00, which is an increase of 198.51% from the latest price.

Price Target
$4.00
(198.51% upside)
Analyst Consensus: Strong Buy